PSA updated: still relevant in the new millennium?

Eur Urol

Department of Urology, Columbia University Medical Center, 161 Fort Washington Avenue, IP-11, New York, NY 10032, USA.

Published: April 2005

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2004.12.020DOI Listing

Publication Analysis

Top Keywords

psa updated
4
updated relevant
4
relevant millennium?
4
psa
1
relevant
1
millennium?
1

Similar Publications

Updates on Recent Advances in the Therapy of Adult Psoriatic Disease.

Curr Rheumatol Rev

January 2025

University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease.

View Article and Find Full Text PDF

Background: Transperineal (TP) biopsy is increasingly used as an alternative to standard transrectal (TR) biopsy for prostate cancer detection to reduce infection risks. However, evidence on comparative diagnostic accuracy remains inconclusive. The aim of this study was to perform an updated systematic review and meta-analysis of studies comparing prostate cancer detection rates between TP and TR ultrasound biopsies.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of additional risk minimization measures (aRMM) for the drug tofacitinib through prescriber surveys across eight European countries from 2021 to 2022.
  • Only a small percentage of surveyed prescribers reported awareness and knowledge of aRMM materials, with low response rates (1.7% for rheumatoid arthritis/psoriatic arthritis and 1.2% for ulcerative colitis).
  • The study concluded that due to the low response rate, surveys alone may not be sufficient for evaluating aRMM effectiveness and suggested that incorporating secondary data could enhance future assessments.
View Article and Find Full Text PDF

Dihydroartemisinin-Piperaquine Combination in the Treatment of Uncomplicated Malaria: Update on Clinical Failures in Africa and Tools for Surveillance.

J Clin Med

November 2024

Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, 13005 Marseille, France.

Dihydroartemisinin (or artenimol)-piperaquine is one of the six artemisinin-based combination therapies recommended in uncomplicated malaria treatment. However, artemisinin partial resistance has been reported in Cambodia, Laos, Vietnam, India, and, recently, in Africa. Polymorphisms in the gene have been described as molecular markers of artemisinin resistance and the amplification of the plasmepsine II/III (/) gene has been associated with piperaquine resistance.

View Article and Find Full Text PDF

Cost-effectiveness of strengthening blood pressure classification in South Korea: comparing the 2017 ACC/AHA and KSH guidelines.

Clin Hypertens

November 2024

Department of Healthcare Management, Graduate School of Public Health, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Background: Hypertension is a significant risk factor for cardiovascular disease (CVD), with hypertension-related deaths increasing annually. While South Korea uses the Korean Society of Hypertension (KSH) guideline of 140/90 mmHg, the American College of Cardiology (ACC) and American Heart Association (AHA) updated their guidelines in 2017 to 130/80 mmHg. This study evaluates the cost-effectiveness of transitioning to the 2017 ACC/AHA guidelines by estimating early treatment impacts and potential CVD risk reduction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!